Germany has not fully realised its biosimilar potential

29 September 2020 - Investigators have concluded that fully realizing the cost-saving potential of biosimilars could “release enormous resources” for ...

Read more →

The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany

15 June 2020 - Payers are increasingly calling for the value of new drugs to be measured explicitly.  ...

Read more →

Underuse of innovative medicines in Germany: A justification for government intervention?

6 December 2018 - The German market for innovative medicines is characterised by simultaneous underuse and overuse.  ...

Read more →

German health minister calls for faster adoption of biosimilar drugs

14 November 2018 - Germany’s health minister Jens Spahn has called for faster adoption of cheaper copies of biotech drugs ...

Read more →